Berberine

Same pharmacology as goldenseal berberine — see goldenseal entry. Sustainable alternative source of berberine

Multiple human RCTs demonstrate metabolic effects on glucose and lipids; extensive animal and mechanistic research; clinical significance of some effects debated

While berberine is present in bloodroot at lower concentrations than sanguinarine, it is one of the most clinically validated botanical alkaloids overall. Extensive clinical trial evidence supports its use for metabolic syndrome, type 2 diabetes, and dyslipidemia when derived from other berberine-rich plants (goldenseal, Oregon grape, barberry). In bloodroot, berberine contributes to the overall antimicrobial spectrum.

Reduced HbA1c comparable to metformin in T2DM RCT (PMID: 18442638). Potent antimicrobial against H. pylori, E. coli, S. aureus. Lipid-lowering via LDLR upregulation (PCSK9 pathway). Anti-inflammatory via NF-kB suppression.

Glucose-lowering comparable to metformin in RCTs. Anti-inflammatory, antimicrobial, and lipid-lowering effects.

Broad-spectrum antimicrobial in vitro; RCTs for blood glucose reduction (comparable to metformin in some studies); significant CYP inhibition confirmed in clinical trials

Extensively studied alkaloid with strong antibacterial, anti-inflammatory, antidiabetic, and lipid-lowering activity in clinical and preclinical studies.

Berberine demonstrates broad-spectrum antimicrobial activity against bacteria, protozoa, and fungi. Clinical trials show efficacy in infectious diarrhea comparable to tetracycline.